Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Monopar Therapeutics Inc shares valued at $34,999,957 were sold by Tactic Pharma LLC on Sep 24 ’25. At $63.61 per share, Tactic Pharma LLC sold 550,229 shares. The insider’s holdings dropped to 272,026 shares worth approximately $23.76 million following the completion of this transaction.
Also, Tsuchimoto Kim R sold 8,904 shares, netting a total of over 356,171 in proceeds. Following the sale of shares at $40.00 each, the insider now holds 11,486 shares.
Before that, STARR CHRISTOPHER M had sold 16,800 shares from its account. In a trade valued at $672,020, the Director traded Monopar Therapeutics Inc shares for $40.00 each. Upon closing the transaction, the insider’s holdings decreased to 16,800 shares, worth approximately $0.45 million.
As published in a research note from Raymond James on November 14, 2025, Monopar Therapeutics Inc [MNPR] has been rated down from a Strong buy to an Outperform. Analysts at Leerink Partners started covering the stock with ‘”an Outperform”‘ outlook in a report released in early November. As of October 13, 2025, Barclays has initiated its “an Overweight” rating for MNPR. Earlier on September 09, 2025, BTIG Research initiated its rating. Their recommendation was “a Buy” for MNPR stock.
Analyzing MNPR Stock Performance
On last trading session, Monopar Therapeutics Inc [NASDAQ: MNPR] plunged -1.25% to $87.36. The stock’s lowest price that day was $83.855, but it reached a high of $88.585 in the same session. During the last five days, there has been a surge of approximately 5.25%. Over the course of the year, Monopar Therapeutics Inc shares have jumped approximately 334.63%. Shares of the company reached a 52-week high of $105.00 on 10/06/25 and a 52-week low of $21.00 on 01/03/25.
Support And Resistance Levels for Monopar Therapeutics Inc (MNPR)
According to the 24-hour chart, there is a support level at 84.52, which, if violated, would cause prices to drop to 81.67. In the upper region, resistance lies at 89.54. The next price resistance is at 91.72. RSI (Relative Strength Index) is 55.08 on the 14-day chart, showing neutral technical sentiment.
Is Monopar Therapeutics Inc subject to short interest?
Stocks of Monopar Therapeutics Inc saw a sharp rise in short interest on 2025-11-14 jumping by 0.21 million shares to 0.37 million. Data from Yahoo Finance shows that the short interest on 2025-10-15 was 0.16 million shares. A jump of 56.37% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 2.78 of the overall float, the days-to-cover ratio (short ratio) jumped to 2.78.
Which companies own the most shares of Monopar Therapeutics Inc (MNPR)?
In terms of Monopar Therapeutics Inc share price expectations, FactSet research, analysts set an average price target of 105 in the next 12 months, up nearly 18.68% from the previous closing price of $88.47. Analysts anticipate Monopar Therapeutics Inc stock to reach 125 by 2025, with the lowest price target being 85. In spite of this, 1 analysts ranked Monopar Therapeutics Inc stock as Buy at the end of 2025. On September 03, 2025, Raymond James assigned a price target of “a Strong buy” to the stock and initiated coverage with a $80.
